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Abstract: The aim of diagnostic medicine research is to estimate
and compare the accuracy of diagnostic tests to provide reliable
information about a patient’s disease status and thereby influencing
patient care. When developing screening tools, researchers evaluate
the discriminating power of the screening test by using simple
measures such as the sensitivity and specificity of the test, as well as
the positive and negative predictive values. In this brief report, we
discuss these simple statistical measures that are used to quantify the
diagnostic ability of a test.
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The purpose of a diagnostic test is to classify or predict thepresence or absence of a disease. The clinical perfor-
mance of a diagnostic test is based on its ability to correctly
classify subjects into relevant subgroups. As new diagnostic
tests are introduced, it is important to evaluate the quality of
the classification obtained from this new test in comparison
with existing tests or the gold standard.
To illustrate the simple measures of diagnostic accu-
racy, consider an example where results from a diagnostic
test such as roentgenogram or computer tomographic scan
and the true disease or condition of the patient is known
(Table 1). The accuracy of any test is measured by comparing
the results from a diagnostic test (positive or negative) with
the true disease using a gold standard (presence or absence)
(see Table 1).1
In this brief report, we first introduce the different
methods used to quantify the diagnostic ability of a test,
namely sensitivity, specificity, likelihood ratio (LR), positive
predictive value, and negative predictive value. We then
discuss the impact of disease prevalence on these measures.
SENSITIVITY AND SPECIFICITY
The two basic measures of quantifying the diagnostic
accuracy of a test are the sensitivity and specificity.1,2 Sen-
sitivity is the ability of a test to detect the disease when it is
truly present, whereas specificity is the probability of a test to
exclude the disease status in patients who do not have the
disease. Thus, sensitivity is given by the ratio of true posi-
tives/(true positives  false negatives), and specificity is
given by the ratio of true negatives/(true negative  false
positives). In the example given in Table 1, the sensitivity is
90% (270/300) and specificity is 60% (60/100).
In describing a diagnostic test, one needs to report both
sensitivity and specificity because they are inherently linked
in that as the value of one increases, the value of the other
decreases. These are also dependent on the patient character-
istics and the disease spectrum, for example, bigger tumors
are easier to detect than smaller benign lesions. In practice,
investigators aim for maximizing both sensitivities and spec-
ificities. Given the financial and emotional implications as-
sociated with a disease process, higher sensitivity is often
considered desirable in a diagnostic setting, and higher spec-
ificity is desirable in a screening set up.
POSITIVE AND NEGATIVE PREDICTIVE VALUES
Clinically, it is always important to know how good the
test is at predicting the true disease status given the findings
from new proposed test. This is captured by the predictive
values. Positive predictive value (PPV) is the probability that
a patient has the disease given that the test results are
positive, and the negative predictive value (NPV) is the
probability that a patient does not have the disease given that
the test results are indeed negative. PPV is therefore given by
the ratio of true positives/(true positives  false positives),
and NPV is given by the ratio of true negatives/(true nega-
tives  false negatives). In the example given in Table 1,
PPV is 87% (270/310) and NPV is 67% (60/90).
PREVALENCE AND ITS IMPACT
Prevalence is defined as the prior probability of the
disease before the test is carried out. Therefore, by definition,
both sensitivity and specificity can be applied to other pop-
ulations that have different prevalence rates. The predictive
values on the other hand are dependent on the prevalence of
the disease being tested.2,3 As described in Table 1, the
disease prevalence in that case is 75% (300/400). Instead,
consider a slightly different scenario in which the disease
prevalence is 50% (200/400) (Table 2).
The sensitivity and specificity are still 90% (180/200),
and 60% (120/200). However, the PPV and NPV are 69%
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(180/260) and 86% (120/140), respectively. Consider another
scenario where the disease prevalence is only 5%. In this
case, the PPV and NPV would be 11% and 99%, respectively.
Thus, the rarer the prevalence of the disease, the more certain
one can be that a negative test result indeed means that there
is no disease (i.e., higher NPV). Similarly, the rarer the
prevalence of the disease, the less certain one can be that a
positive test result indicates the presence of a disease (i.e.,
lower PPV). PPV and NPV estimates obtained from one
study can therefore not be applied universally without infor-
mation on prevalence. In addition, as can be seen by the
examples above, the number of people who are diagnosed as
false positives increases in cases of low prevalence, even
though the sensitivity and the specificity remain high.
LIKELIHOOD RATIO
LR is given by the ratio of the probability of the test
result among patients who truly had the disease to the
probability of the same test among patients who do not have
the disease. In other words, the LR is really the ratio of
sensitivity to (100 Specificity). Therefore, it is independent
of prevalence of the disease. The LR for both examples 1 and
2 is 2.25 (90/[100  60]).
The magnitude of the LR informs about the certainty of
a positive diagnosis. As a general guideline, a value of LR 
1 indicates that the test result is equally likely in patients with
and without the disease, values of LR1 indicate that the test
result is more likely in patients with the disease and values of
LR 1 indicate that the test result is more likely in patients
without the disease.2
SUMMARY
Studies designed to measure the performance of diag-
nostic tests are important for patient care and health care
costs. Attention must be given to include proper representa-
tion of patients with the disease or condition of interest along
with healthy participants to ensure that the study results are
generalizable to the population of interest. Extrapolation of
results obtained from one study to other populations requires
a good understanding of the underlying prevalence and its
impact on the estimates of PPV and NPV.
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TABLE 1. Test Results by Disease Status with Disease
Prevalence of 75%
Test Results
Disease Status (Gold Standard)
TotalPresent Absent
Positive True positive (270) False positive (40) 310
Negative False negative (30) True negative (60) 90
Total 300 100 400
TABLE 2. Test Results by Disease Status with Disease
Prevalence of 50%
Test Results
Disease Status (Gold Standard)
TotalPresent Absent
Positive True positive (180) False positive (80) 260
Negative False negative (20) True negative (120) 140
Total 200 200 400
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